Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effekten av intraoperativ användning av 20 % albumin i kombination med Ringer-laktat kontra Ringer-laktat under cytoreduktiv kirurgi med hypertermisk intraperitoneal kemoterapi: Protokoll för en randomiserad öppen klinisk prövning (ALBUCHIP)

24 september 2026 uppdaterad av: Assistance Publique - Hôpitaux de Paris

Evaluation de l'efficacité du Remplissage Vasculaire Par de l'ALBUmine Humaine 20% + Ringer Lactate comparé au Ringer Lactate Seul Chez Les Patients opérés Par cytoréduction Avec CHimiothérapie Intrapéritonéale hyPerthermique

Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day.

Methods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.

Recruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Information notice and consent form will be delivered. The day before the surgery, anaesthesiologist who will conduct the pre anaesthetic visit will be able to include patients in the study (=inclusion visit). Randomisation will be done at the inclusion visit after information and signature of consent form of voluntary patients. A randomization number will be assigned. The 1:1 randomisation will be centralized via an online interface ensuring secret group assignment, and based on predefined randomisation lists with variable-size permutation blocks, stratified by center. Randomisation will be accomplished using a computer-generated random sequence.

Randomized Open, Blinded endpoint (PROBE) design. This study is a randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.

Intervention

  • 20% Albumin + Ringer Lactate group (intervention group) Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
  • Control group Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.

Outcome measures The primary outcome will be the Comprehensive Complication Index (CCI score) at day 28 after CRS with HIPEC. Secondary outcomes are mortality at day 28, CCI score at day 7, volume of intra operative and post operative (48h) post operative fluid therapy, cumulated incidence of surgical post operative complications, cumulated incidence of medical post operative complications, need for mechanical ventilation, renal replacement therapy between surgery and day 28, SOFA score variation between pre operative period and 48h after surgery, number of days alive out of intensive care unit and out of hospital until day 28

Sample size calculation To ensure a power of 80%, a number of patients 130 (65 patients by group) will be necessary with a reduction of 13.6 (SD 24) points of the CCI score at day 28 in the intervention group. Because of a risk of neoplastic evolution between anaesthetic consultation and randomisation (10% of early cancellation), a total of 146 patients (73 by group) will be included in the study.

Discussion In summary, ALBUCHIP study will be the first randomized clinical trial assessing efficacy of intraoperative use of 20% albumin combined with Ringer Lactate versus Ringer Lactate during CRS with HIPEC. Results yielded from this study will be helpful for vascular filling during CRS with HIPEC but, thanks to ancillary studies, to improve pathophysiological understanding of this surgery.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

140

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Lyon, Frankrike
        • Rekrytering
        • Hôpital Lyon Sud Pierre Bénite
        • Kontakt:
      • Montpellier, Frankrike
        • Rekrytering
        • Institut régional du Cancer de Montpellier
        • Kontakt:
      • Paris, Frankrike, 75013
        • Rekrytering
        • La Pitié Salpetriere hospital
        • Kontakt:
      • Paris, Frankrike
        • Rekrytering
        • Lariboisière hospital
        • Kontakt:
      • Paris, Frankrike
        • Rekrytering
        • Saint Louis hospital
        • Kontakt:
      • Reims, Frankrike
        • Rekrytering
        • Robert Debré hospital
        • Kontakt:
      • Strasbourg, Frankrike
      • Villejuif, Frankrike

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Male and female patients aged 18 years old and older
  • Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)
  • Patient volunteer for the study and provided written informed consent
  • Patient affiliated to the French Health Insurance

Exclusion Criteria:

  • Adults >75 years old
  • Functional status rendering the patient ineligible for cytoreduction with CHIP (ECOG > 2 or Karnofsky index < 75)
  • Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)
  • Severe preoperative hypoalbuminemia (albuminemia < 20 g/L)
  • History of chronic left heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction < 40%)
  • Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)
  • Significant ascites with preoperative respiratory repercussions
  • Uncontrolled diabetes (HbA1c > 8.5%)
  • Allergy to exogenous human albumin and its excipients.
  • Contraindication to the administration of Ringer's lactate (history of allergy)
  • Hyperkalemia > 6.0 mmol/L
  • Hypercalcemia (total calcium > 2.60 mmol/L)
  • Chronic use of digitalis and hyperkalemic diuretics
  • Pregnancy, breastfeeding
  • Known preoperative renal failure (GFR < 30 mL/min/1.73m2 or extrarenal purification)
  • Recent brain trauma < 6 months (traumatic, ischemic, or hemorrhagic)
  • Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable
  • Patient deprived of liberty
  • Patient under guardianship or curatorship

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: 20% Albumin + Ringer Lactate group

Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.

Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.

Aktiv komparator: Control group

Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.

Ringer lactate

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Comprehensive Complication Index score
Tidsram: At day 28

The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery.

The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death

At day 28

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Volym av intraoperativ och postoperativ vätskebehandling
Tidsram: 48 timmar efter operationen
48 timmar efter operationen
Kumulativ incidens av kirurgiska postoperativa komplikationer
Tidsram: Fram till dag 28
Fram till dag 28
Antal dagar vid liv utanför intensivvårdsavdelningen
Tidsram: Fram till dag 28
Fram till dag 28
Antal dagar vid liv utanför sjukhuset
Tidsram: Fram till dag 28
Fram till dag 28
Förekomst av infektionskomplikationer
Tidsram: Upp till dag 28
Upp till dag 28
Förekomst av medicinska komplikationer
Tidsram: Upp till dag 28
Upp till dag 28
Kumulativ incidens av död på intensivvårdsavdelning
Tidsram: Upp till dag 28
Upp till dag 28
Kumulativ incidens av död på sjukhus
Tidsram: Upp till dag 28
Upp till dag 28
Antal dagar med vasopressorer
Tidsram: Upp till dag 28
Upp till dag 28
Andel patienter med allergiska komplikationer till albumin
Tidsram: På dag 133
På dag 133
Comprehensive Complication Index score
Tidsram: At day 7

The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery.

The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death

At day 7
Number of days under mechanical ventilation outside the operating room
Tidsram: Up to day 28

Between surgery and day 28

Up to day 28
Number of days under renal replacement therapy
Tidsram: Up to day 28

Between surgery and day 28

Up to day 28
Sequential organ failure assessment (SOFA) score variation
Tidsram: 48 hours after surgery

Between pre operative period and 48h after surgery

48 hours after surgery
SOFA score
Tidsram: At day 28

Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function

At day 28

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 september 2025

Primärt slutförande (Beräknad)

1 oktober 2027

Avslutad studie (Beräknad)

1 oktober 2027

Studieregistreringsdatum

Först inskickad

2 april 2024

Först inskickad som uppfyllde QC-kriterierna

2 april 2024

Första postat (Faktisk)

8 april 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 september 2026

Senast verifierad

1 november 2025

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera